Oncolytic viruses: A new paradigm for treatment of head and neck cancer

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 113, Issue 2, 2012, Pages 155-160

  Lott, John Bryan ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862576686     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2011.05.021     Document Type: Review

References (39)

1. Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen- Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
3. Hocking JS, Stein A, Conway EL, Regan D, Grulich A, Law M, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011;104:886-91.
4. Ko D, Hawkins L, Yu D. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005;24:7763-74. (Pubitemid 41670678)
5. van Zeeburg HJT, Huizenga A, Brink A, van den Doel PB, Zhu ZB, McCormick F, et al. Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions. Gene Ther 2010;17:1517-24.
6. Hogg RT, Thorpe P, Gerard RD. Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther 2011;18:275-87.
7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
8. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56: 2488-92. (Pubitemid 26170679)
9. Tabor MP, Brakenhoff RH, van Houten VMM, Kummer JA, Snel MHJ, Snijders PJF, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 2001;7:1523-32. (Pubitemid 32708615)
10. Schramek D, Kotsinas A, Meixner A, Wada T, Elling U, Pospisilik JA, et al. The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet 2011;43:212-9.
11. Sheu JJ, Hua C, Wan L, Lin Y, Lai M, Tseng H, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009;69:2568-76.
12. Michikawa C, Uzawa N, Sato H, Ohyama Y, Okada N, Amagasa T. Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer. Br J Cancer 2011;104:850-5.
13. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-73. (Pubitemid 44453332)
14. Ng LK, Rich AM, Hussaini HM, Thomson WM, Fisher AL, Horne LS, et al. Toll-like receptor 2 is present in the microenvironment of oral squamous cell carcinoma. Br J Cancer 2011; 104:460-3.
15. Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009;15:2850-5.
16. Lajer CB, Nielsen FC, Friis-Hansen L, Norrild B, Borup R, Garnæs E, et al. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer 2011;104:830-40.
17. Cervigne NK, Reis PP, Machado J, Sadikovic B, Bradley G, Galloni NN, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 2009;18:4818-29.
18. Cha J, Kim HJ, Cha I. Genetic alterations in oral squamous cell carcinoma progression detected by combining array-based comparative genomic hybridization and multiplex ligation-dependent probe amplification. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:495-607.
19. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500. (Pubitemid 38610250)
20. Schaaij-Visser TBM, Graveland AP, Gauci S, Braakhuis BJM, Buijze M, Heck AJR, et al. Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinomas. Clin Caner Res 2009;15:7666-75.
21. Roblyer D, Kurachi C, Stepanek V, Williams MD, El-Naggar AK, Lee JJ, et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer. Prev Res 2009;2:423-31.
22. Lane DP, Cheok CF, Lain S. Based cancer therapy. In: Levine AJ, Lane DP, editors. The p53 family. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2010. p. 293-316.
23. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-60. (Pubitemid 46232886)
24. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21: 6041-8.
25. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumour suppressor function to mutant p53 by a low molecular compound. Nat Med 2002;8:282-8. (Pubitemid 34250107)
26. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
27. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005;24:7802-16. (Pubitemid 41670681)
28. Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005;24:7673-85. (Pubitemid 41670670)
29. Savelyeva I, Dobbelstein M. Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A. Oncogene 2011;30:865-75.
30. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral injection and DNA transfection. Virology 1997;156:107-21.
31. Shi J, Zheng D. An update on gene therapy in China. Curr Opin Mol Ther 2009;11:547-53.
32. Rudin CM, Cohen EEW, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003;21:4546-52. (Pubitemid 46594025)
33. Zhu ZB, Chen Y, Makhija S, Lu B, Wang M, Rivera A, et al. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int J Oncol 2006;29:1319-29.
34. Doloff JC, Waxman DJ, Dual E. 1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther 2011;18:153-66.
35. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. (Pubitemid 43209104)
36. Cherry T, Longo SL, Tovar-Spinoza Z, Post DE. Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy. Gene Ther 2010;17:1430-41.
37. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-65.
38. Longo SL, Griffith C, Glass A, Shillitoe EJ, Post DE. Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter. Cancer Gene Ther 2011;18:123-34.
39. Cody JJ, Rivera AA, Lyons GR, Yang SW, Wang M, Sarver DB, et al. Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer. Cancer Gene Ther 2010;17:893-905.